A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation (clinicaltrials.gov) - Sep 11, 2026 - P1 | N=16 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Incorporated
New P1 trial • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases
|